1. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper
J, de Witte T, Schaap N, Dolstra H. Clinical-grade generation of active NK cells from
cord blood hematopoietic progenitor cells for immunotherapy using a
closed-system culture process. PloS one, 2011.
6(6): e20740.
2. Broen K, Levenga H, Vos J, van Bergen K, Fredrix H,
Greupink-Draaisma A, Kester M, Falkenburg JH, de Mulder P, de Witte
T, Griffioen M, Dolstra H. A Polymorphism in the Splice Donor Site of ZNF419
Results in the Novel Renal Cell Carcinoma-Associated Minor
Histocompatibility Antigen ZAPHIR. PloS one,
2011. 6(6): e21699.
3. de Keijzer S, Meddens MB, Kilic D, Joosten B,
Reinieren-Beeren I, Lidke DS, Cambi A. Interleukin-4 Alters Early Phagosome Phenotype by
Modulating Class I PI3K Dependent Lipid Remodeling and Protein
Recruitment. PloS one, 2011. 6(7): e22328.
4. Oosting M, Ter Hofstede H, Sturm P, Adema GJ, Kullberg BJ,
van der Meer JW, Netea MG, Joosten LA. TLR1/TLR2 Heterodimers Play an Important Role in
the Recognition of Borrelia Spirochetes. PloS
one, 2011. 6(10): e25998.
5. Tel J, Torensma R, Figdor CG, de Vries IJ. IL-4 and IL-13 alter plasmacytoid dendritic cell
responsiveness to CpG DNA and herpes simplex virus-1. J
Invest Dermatol, 2011. 131(4): 900-6.
6. Tel J, Benitez-Ribas D, Hoosemans S, Cambi A, Adema GJ,
Figdor CG, Tacken PJ, de Vries IJ. DEC-205 mediates antigen uptake and presentation by
both resting and activated human plasmacytoid dendritic cells.
Eur J Immunol, 2011. 41(4): 1014-23.
7. Plantinga TS, van Maren WW, van Bergenhenegouwen J, Hameetman
M, Nierkens S, Jacobs C, de Jong DJ, Joosten LA, van't Land B,
Garssen J, Adema GJ, Netea MG. Differential Toll-like receptor recognition and
induction of cytokine profile by Bifidobacterium breve and
Lactobacillus strains of probiotics. Clinical and
vaccine immunology : CVI, 2011. 18(4): 621-8.
8. van Spriel AB. Tetraspanins in the humoral immune response.
Biochemical Society transactions, 2011. 39(2):
512-7.
9. Cruz LJ, Tacken PJ, Bonetto F, Buschow SI, Croes HJ, Wijers
M, de Vries IJ, Figdor CG. Multimodal imaging of nanovaccine carriers targeted
to human dendritic cells. Molecular
pharmaceutics, 2011. 8(2): 520-31.
10. Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R,
Massuger LF. Cytokine analysis as a tool to understand
tumour-host interaction in ovarian cancer. European
journal of cancer, 2011. 47(12): 1883-9.
11. Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix
H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini
P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G.
Tandem autologous/reduced-intensity conditioning
allogeneic stem-cell transplantation versus autologous
transplantation in myeloma: long-term follow-up.
Journal of clinical oncology : official journal of the
American Society of Clinical Oncology, 2011. 29(22):
3016-22.
12. Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D,
Jansen BJ, Nierkens S, Schreibelt G, de Boer A, Van Herpen CM,
Kaanders JH, van Krieken JH, Adema GJ, Figdor CG, de Vries IJ. Platinum-based drugs disrupt STAT6-mediated
suppression of immune responses against cancer in humans and
mice. The Journal of clinical investigation,
2011. 121(8): 3100-8.
13. Zeelenberg IS, van Maren WW, Boissonnas A, Van Hout-Kuijer
MA, Den Brok MH, Wagenaars JA, van der Schaaf A, Jansen EJ,
Amigorena S, Thery C, Figdor CG, Adema GJ. Antigen localization controls T cell-mediated tumor
immunity. Journal of immunology, 2011. 187(3):
1281-8.
14. Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG,
Hebeda K, Falkenburg JH, Schaap N, de Witte TM, van der Voort R,
Dolstra H. PD-1/PD-L1 Interactions Contribute to Functional
T-Cell Impairment in Patients Who Relapse with Cancer After
Allogeneic Stem Cell Transplantation. Cancer
research, 2011. 71(15): 5111-22.
15. Veenbergen S, van Spriel AB. Tetraspanins in the immune response against
cancer. Immunology letters, 2011. 138(2):
129-36.
16. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van
de Glind G, Fokkink RG, Lambeck AJ, Figdor CG. Targeted delivery of TLR ligands to human and mouse
dendritic cells strongly enhances adjuvanticity.
Blood, 2011. 118(26): 6836-44.
17. Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM,
Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor
CG, de Vries IJ, Punt CJ. Wild-type and modified gp100 peptide-pulsed
dendritic cell vaccination of advanced melanoma patients can lead
to long-term clinical responses independent of the peptide
used. Cancer Immunol Immunother, 2011. 60(2):
249-60.
18. Tacken PJ, Figdor CG. Targeted antigen delivery and activation of
dendritic cells in vivo: Steps towards cost effective vaccines.
Seminars in immunology, 2011. 23(1): 12-20.
19. Kroger N, Zabelina T, van Biezen A, Brand R, Niederwieser D,
Martino R, Lim ZY, Onida F, Schmid C, Garderet L, Robin M, van
Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T. Allogeneic stem cell transplantation for
myelodysplastic syndromes with bone marrow fibrosis.
Haematologica, 2011. 96(2): 291-7.
20. van den Berk LCJ, Jansen BJH, Siebers-Vermeulen KGC, Huijsi
T, Roelofs H, Kogler G, Figdor CG, Torensma R. The
Tissue Origin and Culture History of Mesenchymal Stem Cells Affect
their Performance in Osteoblastic Differentiation.
Tissue Engineering and Regenerative Medicine,
2011. 8(1): 96-105.
21. Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os
M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W,
Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M,
Milligan D. Autologous hematopoietic stem cell transplantation
in chronic lymphocytic leukemia: results of European intergroup
randomized trial comparing autografting versus observation.
Blood, 2011. 117(5): 1516-21.
22. de Vries IJ, Castelli C, Huygens C, Jacobs JF, Stockis J,
Schuler-Thurner B, Adema GJ, Punt CJ, Rivoltini L, Schuler G,
Coulie PG, Lucas S. Frequency of Circulating Tregs with Demethylated
FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and
Potentially Treg-Depleting Agents. Clin Cancer
Res, 2011. 17(4): 841-8.
23. Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani
M, Barbui T, Barosi G, Bassan R, Bene MC, Berger U, Buchner T,
Burnett A, Cross NC, de Witte TJ, Dohner H, Dombret H, Einsele H,
Engelich G, Foa R, Fonatsch C, Gokbuget N, Gluckman E, Gratwohl A,
Guilhot F, Haferlach C, Haferlach T, Hallek M, Hasford J, Hochhaus
A, Hoelzer D, Kiladjian JJ, Labar B, Ljungman P, Mansmann U,
Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H,
Schrotz-King P, Sanz MA, Saussele S. The European LeukemiaNet: achievements and
perspectives. Haematologica, 2011. 96(1):
156-62.
24. Robin M, Sanz GF, Ionescu I, Rio B, Sirvent A, Renaud M,
Carreras E, Milpied N, Mohty M, Beguin Y, Bordigoni P, de Witte T,
Picardi A, Purtill D, Gluckman E, Kroger N, Rocha V. Unrelated cord blood transplantation in adults with
myelodysplasia or secondary acute myeloblastic leukemia: a survey
on behalf of Eurocord and CLWP of EBMT. Leukemia :
official journal of the Leukemia Society of America, Leukemia
Research Fund, U.K, 2011. 25(1): 75-81.
25. Di J, Duiveman-de Boer T, Figdor CG, Torensma R. Eradicating cancer cells: struggle with a
chameleon. Oncotarget, 2011. 2(1-2):
99-101.
26. van Bijnen ST, Withaar M, Preijers F, van der Meer A, de
Witte T, Muus P, Dolstra H. T cells expressing the activating NK-cell receptors
KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal
hemoglobinuria and cytotoxic toward hematopoietic progenitor cell
lines. Experimental hematology, 2011. 39(7):
751-62 e3.
27. Mulder SF, Jacobs JF, Olde Nordkamp MA, Galama JM, Desar IM,
Torensma R, Teerenstra S, Mulders PF, Vissers KC, Punt CJ, de Vries
IJ, van Herpen CM. Cancer patients treated with sunitinib or sorafenib
have sufficient antibody and cellular immune responses to warrant
influenza vaccination. Clin Cancer Res, 2011.
17(13): 4541-9.
28. Theodoridis AA, Eich C, Figdor CG, Steinkasserer A. Infection of dendritic cells with herpes simplex
virus type 1 induces rapid degradation of CYTIP, thereby modulating
adhesion and migration. Blood, 2011. 118(1):
107-15.
29. de Witte T. Allogeneic stem cell transplantation for
myelodysplastic syndromes: critical for cure?. Clinical
lymphoma, myeloma & leukemia, 2011. 11 Suppl 1:
S46-8.
30. Jansen BJ, Sama IE, Eleveld-Trancikova D, van Hout-Kuijer
MA, Jansen JH, Huynen MA, Adema GJ. MicroRNA genes preferentially expressed in
dendritic cells contain sites for conserved transcription factor
binding motifs in their promoters. BMC
genomics, 2011. 12(1): 330.
31. Verstappen J, Katsaros C, Kuijpers-Jagtman AM, Torensma R,
Von den Hoff JW. The recruitment of bone marrow-derived cells to
skin wounds is independent of wound size. Wound repair
and regenerationSociety, 2011. 19(2): 260-7.
32. Eich C, de Vries IJ, Linssen PC, de Boer A, Boezeman JB,
Figdor CG, Cambi A. The lymphoid chemokine CCL21 triggers LFA-1
adhesive properties on human dendritic cells.
Immunology and cell biology, 2011. 89(3):
458-65.
33. de Vries IJ, Tel J, Benitez-Ribas D, Torensma R, Figdor CG.
Prophylactic vaccines mimic synthetic CpG
oligonucleotides in their ability to modulate immune responses.
Molecular immunology, 2011. 48(6-7): 810-7.
34. Chai LY, de Boer MG, van der Velden WJ, Plantinga TS, van
Spriel AB, Jacobs C, Halkes CJ, Vonk AG, Blijlevens NM, van Dissel
JT, Donnelly PJ, Kullberg BJ, Maertens J, Netea MG. The Y238X stop codon polymorphism in the human
beta-glucan receptor dectin-1 and susceptibility to invasive
aspergillosis. The Journal of infectious
diseases, 2011. 203(5): 736-43.
35. van Maren WW, Nierkens S, Toonen LW, Bolscher JM, Sutmuller
RP, Adema GJ. Multifaceted effects of synthetic TLR2 ligand and
Legionella pneumophilia on Treg-mediated suppression of T cell
activation. BMC immunology, 2011. 12(1):
23.
36. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U,
Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens
F, Muus P, Pfluger KH, Coens C, Hagemeijer A, Eckart Schaefer H,
Ganser A, Aul C, de Witte T, Wijermans PW. Low-Dose Decitabine Versus Best Supportive Care in
Elderly Patients With Intermediate- or High-Risk Myelodysplastic
Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results
of the Randomized Phase III Study of the European Organisation for
Research and Treatment of Cancer Leukemia Group and the German MDS
Study Group. Journal of clinical oncology,
2011. 29(15): 1987-96.
37. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon
C, Cornelissen J, de Witte T, Ljungman P, McDonald F, McGrath E,
Passweg J, Peters C, Rocha V, Slaper-Cortenbach I, Sureda A,
Tichelli A, Apperley J. Introduction of a quality management system and
outcome after hematopoietic stem-cell transplantation.
Journal of clinical oncology, 2011. 29(15):
1980-6.
38. Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis
WJ, Windhorst AD, Troost EG, Bonenkamp JJ, van Rossum MM, Blokx WA,
Mus RD, Boerman OC, Punt CJ, Figdor CG, Oyen WJ, de Vries IJ. Early identification of antigen-specific immune
responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine
([18F]FLT) PET imaging. Proc Natl Acad Sci U S
A, 2011. 108(45): 18396-9.
39. Cruz LJ, Tacken PJ, Fokkink R, Figdor CG. The influence of PEG chain length and targeting
moiety on antibody-mediated delivery of nanoparticle vaccines to
human dendritic cells. Biomaterials, 2011.
32(28): 6791-803.
40. van Bijnen ST, Vermeer H, Mourisse JM, de Witte T, van
Swieten HA, Muus P. Cardiopulmonary bypass in a patient with classic
paroxysmal nocturnal hemoglobinuria during treatment with
eculizumab. European journal of haematology,
2011. 87(4): 376-8.
41. Yigit R, Massuger LF, Zusterzeel PL, Pots J, Figdor CG,
Torensma R. Cytokine profiles in cyst fluids from ovarian
tumors reflect immunosuppressive state of the tumor.
Int J Gynecol Cancer, 2011. 21(7): 1241-7.
42. Sanecka A, Ansems M, Prosser AC, Danielski K, Warner K, den
Brok MH, Jansen BJ, Eleveld-Trancikova D, Adema GJ. DC-STAMP knock-down deregulates cytokine production
and T-cell stimulatory capacity of LPS-matured dendritic cells.
BMC immunology, 2011. 12(1): 57.
43. Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser
T, Figdor CG, Cambi A. Targeting DC-SIGN via its neck region leads to
prolonged antigen residence in early endosomes, delayed lysosomal
degradation, and cross-presentation. Blood,
2011. 118(15): 4111-9.
44. Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenaars J,
Wassink M, Boon L, Ruers TJ, Figdor CG, Schoenberger SP, Adema GJ,
Janssen EM. Immune Adjuvant Efficacy of CpG Oligonucleotide in
Cancer Treatment Is Founded Specifically upon TLR9 Function in
Plasmacytoid Dendritic Cells. Cancer research,
2011. 71(20): 6428-37.
45. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ,
Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ,
Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S,
Adema GJ, Punt CJ, Figdor CG. Route of administration modulates the induction of
dendritic cell vaccine-induced antigen-specific T cells in advanced
melanoma patients. Clin Cancer Res, 2011.
17(17): 5725-35.
46. Bonetto F, Srinivas M, Heerschap A, Mailliard R, Ahrens ET,
Figdor CG, de Vries IJ. A Novel (19)F agent for detection and
quantification of human dendritic cells using magnetic resonance
imaging. Int J Cancer, 2011. 129(2):
365-73.
47. Desar IM, Jacobs JF, Stillebroer AB, Hulsbergen-Vandekaa CA,
Oyen WJ, Mulders PF, van der Graaf WT, Adema GJ, van Herpen CM, de
Vries IJ. Sorafenib reduces the percentage of tumour
infiltrating regulatory T cells in renal cell carcinoma
patients. Int J Cancer, 2011. 129(2):
507-12.
48. Te Riet J, Katan AJ, Rankl C, Stahl SW, van Buul AM, Phang
IY, Gomez-Casado A, Schon P, Gerritsen JW, Cambi A, Rowan AE,
Vancso GJ, Jonkheijm P, Huskens J, Oosterkamp TH, Gaub H,
Hinterdorfer P, Figdor CG, Speller S. Interlaboratory round robin on cantilever
calibration for AFM force spectroscopy.
Ultramicroscopy, 2011. 111(12): 1659-69.